Skip to content
Screener

CapEx at other companies

CareDx logo
CareDxCDNA
$3.82M+134%
LivaNova logo
LivaNovaLIVN
$31.55M+108%
SRT
Strata Critical MedicalSRTA
$5.18M+98.1%
Insight Molecular Diagnostics Inc. logo
Insight Molecular Diagnostics Inc.IMDX
$613K+99.7%
ICU Medical logo
ICU MedicalICUI
$18.51M-6.0%
Stereotaxis logo
StereotaxisSTXS
$79K

Other financials

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
Net income$7.3M-71.5%
EPS (diluted)$0.20-71.4%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
Operating cash flow$24.5M+959%
Free cash flow-$12.1M+59.4%

Valuation

See full
Market cap$2.78B-31.3%
Enterprise value$2.73B-26.6%
P/E16.2×-40.3×
P/S4.4×-3.2×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Where this comes from

Reported directly by TransMedics Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The source filing: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206453
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Operating lease liabilities(805)(664)
Net cash provided by (used in) operating activities24,533(2,855)
Cash flows from investing activities:
Purchases of property, plant and equipment(36,657)(27,038)
Net cash used in investing activities(36,657)(27,038)
Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of stock options2,2121,742
Proceeds from issuance of common stock in connection with employee stock purchase plan1,6881,286

Item 1. Financial Statements (Unaudited)

FAQ

What is TransMedics Group, Inc.'s capex?
TransMedics Group, Inc. (TMDX) reported capex of $36.66M in Q1 2026.
How has TransMedics Group, Inc.'s capex changed year-over-year?
TransMedics Group, Inc.'s capex increased by 35.6% year-over-year, from $27.04M to $36.66M.
What is the long-term trend for TransMedics Group, Inc.'s capex?
Over 4 years (2021 to 2025), TransMedics Group, Inc.'s capex has grown at a 102.6% compound annual growth rate (CAGR), from $3.52M to $59.25M.
What does capex mean?
Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.

Ask your AI about TransMedics Group, Inc.'s capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude